nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Depression Symptoms Soar During Pandemic, Study Finds
September 28, 2020   

The coronavirus disease 2019 (COVID-19) pandemic has been a traumatic event that is compounded by the policies enacted to prevent its spread, which have introduced new life stressors and disrupted daily living for most people in the United States (US). Early evidence suggests that...
 Continue reading (Members only)
FDA Requiring Stronger Warning Label For Benzodiazepines
September 25, 2020   

The US Food and Drug Administration has ordered changes to the labeling for benzodiazepines, requiring them to include information on the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions. Benzodiazepines are...
 Continue reading
Prevalence and Risk Factors Associated With Attention-Deficit/Hyperactivity Disorder Among US Black Individuals
September 24, 2020   

The worldwide prevalence of attention deficit/hyperactivity disorder (ADHD) is estimated to be 5.6%-7.2%. Prevalence rates of ADHD among Black individuals are reported to be lower than the rates of the general population. However, there is a paucity of primary studies with appropriate methodological design...
 Continue reading (Members only)
Offspring of Women With Polycystic Ovary Syndrome Have Increased Risk Of Psychiatric Disorders
September 21, 2020   

A new, a population-based cohort study has found that children who are born to women who are living with polycystic ovary syndrome have an increased risk of psychiatric disorders....
 Continue reading
Refreshing Perspectives on Recovery: September is National Recovery Month with Dr. Nzinga Harrison
September 17, 2020   

In this invigorating interview with addiction expert, Dr. Nzinga Harrison, we discuss the need for removing the stigma and misconceptions surrounding the topic of addiction, and how to apply treatment strategies focused on understanding compassion, and evidence-based scientific research...
 Continue reading
New Schizophrenia Treatment Guidelines Released by APA
September 14, 2020   

The American Psychiatric Association (APA) has just released its latest guidelines for the treatment of patients with schizophrenia. These new guidelines are the first APA schizophrenia guidelines to be published in over a decade. During that 10+ year interim, there have been many advancements in...
 Continue reading (Members only)
Antihypertensive Drugs Associated With Reduced Risk for Depression
September 11, 2020   

A list of nine antihypertensive medications were associated with decreased risk of depression in a recently published population-based study. The risk of a diagnosis of depression was evaluated in patients taking any of forty-one antihypertensive therapies in four major drug categories...
 Continue reading (Members only)
Olanzapine/Samidorphan Combo Found to Reduce Antipsychotic-Induced Weight Gain
September 1, 2020   

The combination of olanzapine, a dopamine D2 receptor antagonist, and samidorphan, an opioid receptor antagonist, is being developed for the treatment of schizophrenia and bipolar I disorder. Despite its efficacy, olanzapine is associated with significant weight gain and adverse metabolic effects that limit its clinical utility as a monotherapy. The combination of olanzapine and samidorphan has been shown to...
 Continue reading (Members only)
Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects
August 28, 2020   

Between 6% and 8% of United States pregnant women are prescribed antidepressants. However, concerns remain about the adverse effects of antidepressants on fetal and infant health, including birth defect risk after early pregnancy exposure. The current study addresses this concern by examining the...
 Continue reading
Systolic Orthostatic Hypotension Tied to Dementia Risk
August 21, 2020   

A recent study examined whether orthostatic hypotension and visit-to-visit blood pressure postural changes variability are associated with incident dementia. The study involved 2,131 people aged 73 years old on average. Repeatedly over a period of five years, researchers A recent study examined whether orthostatic hypotension and visit-to-visit blood pressure postural changes variability are associated with incident dementia. The study involved 2,131 people aged 73 years old on average. Over a period of five years, researchers...
 Continue reading (Members only)
12345678910...
Top of Page